Cancer Research and Treatment

Original Articles

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer: Ji-Youn Han, Geon Kook Lee, Kun Young Lim, Young Ju Lee, Byung Ho Nam, Jin Soo Lee; Cancer Res Treat. 2017;49(3):678-687. Published online October 11, 2016; DOI: https://doi.org/10.4143/crt.2016.365

Abstract PDF Supplementary Material PubReader ePub

Purpose
We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Materials and Methods
Eligible patients were randomly assigned to the GP (gemcitabine 1,250 mg/m² on days 1 and 8, and cisplatin 75 mg/m² on day 1 every 3 weeks) or IP (irinotecan 65 mg/m² and cisplatin 30 mg/m² on days 1 and 8 every 3 weeks) arm. The primary goal of this study was to compare the response rate (RR) of the GP and IP arms according to the ERCC1 expression level.
Results
A total of 279 patients were randomly assigned to the GP (n=139) and IP (n=140) arms, among which 63% were ERCC1-positive and 268 patients were assessable for the RR. The GP and IP arms did not differ significantly with respect to the RR (29.8% vs. 27.0%, respectively; p=0.082), median progression-free survival (PFS; 4.5 months vs. 3.9 months, respectively; p=0.117), and overall survival (OS; 16.5 months vs. 16.7 months, respectively; p=0.313). When comparing the efficacy between the ERCC1-positive and ERCC1-negative groups, there was no significant difference in the RR (GP, 28.2% vs. 32.6%, respectively, p=0.509; IP, 30.2% vs. 21.6%, respectively, p=0.536), median PFS (GP, 4.6 months vs. 5.0 months, respectively, p=0.506; IP, 3.9 months vs. 3.7 months, respectively, p=0.748), or median OS (GP, 18.6 months vs. 11.9 months, respectively, p=0.070; IP, 17.5 months vs. 14.0 months, respectively, p=0.821).
Conclusion
Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC.

Citations

Citations to this article as recorded by

Meta‐Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non‐Small‐Cell Lung Cancer
Guoping Li, Dan Cheng, Jamal A. Mahajna
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef
The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma
Yu-Liang Huang, Jun-Rong Wu, Min Fang, Hui-Liu Zhao, Zhi-Min Liu, Jian Ye, Ling-Sha Huang, Bo Zhu
Medicine.2019; 98(14): e15090. CrossRef

12,570 View
200 Download
5 Web of Science
2 Crossref

Interaction between Genetic Polymorphisms of CYP2E1 & NAT1 and Smoking in Lung Cancer Development (Preliminary report): Kyoung Mu Lee, Seung Joon Lee, Sue Kyung Park, Sang Yun Lee, Hyung June Im, Ki Jung Yoon, In Mi Choi, Young Ju Lee, Soo Ung Kim, Hwang Choi, Seung Ho Choi, Young Whan Kim, Soo Han Cho, Daehee Kang; J Korean Cancer Assoc. 2001;33(1):41-48.

Abstract PDF: PURPOSE
The interactive effects of genetic polymorphisms of cytochrome P4502E1 (CYP2E1) & N-acetyltransferase 1 (NAT1) and smoking on lung cancer development were evaluated in hospital based case-control study.
MATERIALS AND METHODS
Male lung cancer patients (N= 157) and the male patients with no present or previous history of systemic illnesses who visited the urology department (N=138) were recruited (1998-1999). CYP2E1 & NAT1 genotypes were determined by PCR-RFLP method using RsaI and MboII digestion, respectively.
RESULTS
CYP2E1 c2 or NAT1 *10 allele did not increased the risk of lung cancer. Heavy smokers (35CONCLUSION
These results suggest the gene-environment interaction between genetic polymorphisms of CYP2E1 & NAT1 and smoking in lung cancer development.

4,190 View
25 Download

First
Prev
Page of 1
Next
Last

Search